ArticleNeuropsychiatric disease and treatment2026
Celecoxib Ameliorates Chronic Restraint Stress-Induced Depression-Like Behavior in Sprague-Dawley Rats.
Article in Neuropsychiatric disease and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Chronic stress is associated with depressive-like behaviors, dysregulation of the hypothalamic-pituitary-adrenal axis, and changes in inflammatory signaling. Celecoxib is a selective cyclooxygenase-2 inhibitor that has been investigated as a potential adjunctive treatment for depression; however, its effects in a chronic restraint stress model require further characterization. Methods: Male Sprague-Dawley rats were randomly assigned to a control group, chronic restraint stress (CRS) model group, CRS plus celecoxib group, or CRS plus fluoxetine group. The CRS procedure was conducted for 6 weeks, with restraint applied for 4 h per day. Celecoxib was administered by oral gavage at a dose of 20 mg/kg/day, and fluoxetine was administered at 10 mg/kg/day for 2 weeks throughout the CRS procedure. Depression-like and related behavioral changes were evaluated using the open field test, forced swimming test, Y-maze test, and sucrose preference test. Cytokine and corticosterone concentrations were measured in hippocampal homogenates. Hippocampal IBA-1 immunoreactivity and histological changes were evaluated using immunofluorescence, H&E staining, Nissl staining, and transmission electron microscopy. Results: Compared with control rats, CRS-exposed rats showed changes in open-field activity, forced-swimming behavior, Y-maze performance, and sucrose preference. Celecoxib treatment was associated with improved behavioral parameters compared with the CRS model group. Celecoxib was also associated with lower concentrations of IL-1β, IL-6, TNF-α, and corticosterone, reduced hippocampal IBA-1 immunoreactivity, and less pronounced histological and ultrastructural alterations. Discussion: These findings indicate that celecoxib was associated with improved behavioral outcomes and reduced inflammatory, endocrine, histological, and ultrastructural alterations in CRS-exposed rats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.